Monograph of Losartan

Introduction/Overview

Losartan is a selective antagonist of the angiotensin II type 1 (AT₁) receptor, widely employed in the management of hypertension and heart failure. Its introduction has markedly altered therapeutic strategies for cardiovascular disease, offering an alternative for patients intolerant to conventional beta‑blockers or diuretics. The clinical significance of losartan extends to renal protection in diabetic nephropathy and to the attenuation of left ventricular remodeling following myocardial infarction. Consequently, a comprehensive understanding of its pharmacologic profile is essential for both clinicians and pharmacy professionals.

Learning objectives for this chapter include:

• Identify the chemical and therapeutic classification of losartan.
• Explain the pharmacodynamic mechanisms underlying AT₁ receptor blockade.
• Describe the absorption, distribution, metabolism, and excretion characteristics of losartan and its active metabolite.
• Outline approved indications and discuss common off‑label applications.
• Recognize typical adverse effects, serious risks, and pertinent drug interactions.
• Apply knowledge of special patient populations, including pregnancy, pediatrics, geriatrics, and those with organ impairment.

Classification

Drug Classes and Categories

Losartan belongs to the class of angiotensin II receptor blockers (ARBs), a group of antihypertensive agents that inhibit the effects of angiotensin II by competitively occupying the AT₁ receptor. ARBs differ from angiotensin-converting enzyme (ACE) inhibitors in that they target downstream signaling without influencing bradykinin metabolism. Within the ARB class, losartan is distinguished by its relatively short half‑life and the presence of an active metabolite, EXP3174, which contributes significantly to its therapeutic efficacy.

Chemical Classification

A chemically, losartan is a heterocyclic compound featuring a tetrazole ring, a benzyl substituted pyrimidine moiety, and a side chain containing a carboxylic acid derivative. Its molecular formula is C₂₂H₂₅N₅O₄, with a molecular weight of 445.5 g·mol^-1. The presence of the tetrazole group confers high affinity for the AT₁ receptor, while the pyrimidine ring enhances selectivity by favoring receptor binding over off‑target interactions. Losartan is typically administered as the free base, with a commercially available salt form—losartan potassium hydrate—to improve aqueous solubility and bioavailability.

Mechanism of Action

Pharmacodynamics

Losartan exerts its antihypertensive effect by competitively inhibiting angiotensin II binding to the AT₁ receptor, thereby attenuating vasoconstriction, sodium retention, and sympathetic activation. Inhibition of AT₁ receptor signaling reduces intracellular calcium mobilization, leading to vasodilation of both arteriolar and venous beds. Concurrently, suppression of aldosterone synthesis enhances natriuresis and diuresis, contributing to the reduction of extracellular fluid volume. The cumulative result is a sustained decrease in systemic vascular resistance and arterial blood pressure.

Receptor Interactions

Losartan displays high affinity for the AT₁ receptor due to the tetrazole ring’s ability to form hydrogen bonds with receptor residues. The active metabolite, EXP3174, possesses a binding affinity approximately 4–5 times greater than the parent compound, amplifying the therapeutic response. The selectivity profile of losartan ensures minimal interaction with the AT₂ receptor, which mediates vasodilatory and antiproliferative effects; thus, losartan’s blockade preserves the beneficial actions of AT₂ signaling. Additionally, losartan does not appreciably inhibit ACE activity, thereby avoiding the bradykinin‑related cough and angioedema associated with ACE inhibitors.

Molecular/Cellular Mechanisms

At the cellular level, losartan disrupts downstream signaling cascades initiated by angiotensin II. The inhibition of AT₁ receptor activation prevents the stimulation of phospholipase C, which would otherwise generate inositol triphosphate and diacylglycerol. Consequently, the release of intracellular calcium stores is curtailed, leading to reduced smooth muscle contraction. Moreover, losartan impedes the activation of the nuclear factor kappa‑B (NF‑κB) pathway, thereby attenuating pro‑inflammatory cytokine production and fibrosis. In renal tissue, these effects translate into decreased glomerular hypertension and proteinuria, explaining the renoprotective benefits observed in diabetic nephropathy trials.

Pharmacokinetics

Absorption

Oral administration of losartan results in rapid absorption, with peak plasma concentrations (C_max) achieved approximately 1–2 hours post‑dose. Bioavailability is relatively low (~33%) due to first‑pass hepatic metabolism; however, the formation of the active metabolite compensates for this limitation. Food intake modestly delays absorption but does not significantly alter overall bioavailability. The dissolution of the drug in the gastrointestinal tract is facilitated by its moderate lipophilicity, allowing adequate penetration across the mucosal barrier.

Distribution

Losartan distributes extensively throughout the body, with a volume of distribution (V_d) estimated at 5–10 L·kg^-1. The drug exhibits moderate protein binding (~70%) primarily to albumin, which permits a substantial free fraction capable of receptor interaction. Tissue penetration is sufficient to reach vascular smooth muscle and renal cortical cells, as evidenced by the drug’s therapeutic effects in both systemic and renal compartments. The active metabolite, EXP3174, demonstrates similar distribution characteristics, ensuring consistent pharmacologic activity.

Metabolism

Hepatic metabolism predominates, involving oxidative pathways mediated by cytochrome P450 isoenzymes. The primary metabolic conversion of losartan to EXP3174 occurs via CYP2C9 and CYP3A4, with CYP2C9 contributing approximately 30% to the overall metabolic flux. Subsequent biotransformation yields several inactive metabolites, which are excreted via renal and biliary routes. Because losartan is not a potent inhibitor or inducer of CYP enzymes, significant drug–drug interactions through metabolic pathway modulation are uncommon, although caution is advised with potent CYP inhibitors that may elevate plasma concentrations.

Excretion

Renal excretion constitutes the principal elimination pathway. The parent compound and its metabolites are eliminated via glomerular filtration and tubular secretion. The active metabolite, EXP3174, is cleared with a half‑life (t_1/2) of approximately 6–9 hours, whereas the parent drug has a shorter half‑life (~1–2 hours). In patients with impaired renal function, clearance of both the parent drug and metabolite is reduced, necessitating dose adjustment to avoid accumulation. Biliary excretion of minor metabolites contributes to overall elimination but is negligible compared to renal pathways.

Half‑Life and Dosing Considerations

The pharmacokinetic profile of losartan supports once‑daily dosing at therapeutic concentrations. Standard dosing ranges from 25 to 100 mg once daily, with titration guided by blood pressure response and tolerance. In patients with moderate renal impairment (creatinine clearance 30–59 mL·min^-1), the maximum recommended dose is 50 mg daily. For severe impairment (creatinine clearance <30 mL·min^-1), dosage should be limited to 25 mg daily or considered contraindicated. Hepatic dysfunction has a minimal impact on losartan clearance due to the predominance of renal elimination. Concomitant use of potassium‑sparing diuretics or potassium supplements requires monitoring of serum potassium levels to prevent hyperkalemia.

Therapeutic Uses/Clinical Applications

Approved Indications

Losartan is approved for the treatment of essential hypertension, both as monotherapy and in combination with other antihypertensive agents. It is also indicated for the reduction of cardiovascular risk in patients with hypertension and left ventricular hypertrophy, as well as for the prevention of progression of diabetic nephropathy in patients with type 2 diabetes mellitus and microalbuminuria. Additionally, losartan may be employed in the management of heart failure with reduced ejection fraction, particularly when ACE inhibitor therapy is contraindicated or poorly tolerated.

Off‑Label Uses

Although not formally approved for these indications, losartan is frequently utilized off‑label to treat preeclampsia in pregnancy, given its favorable safety profile relative to ACE inhibitors. In this context, dosages are typically limited to 50 mg daily to mitigate potential fetal adverse effects. Losartan is also applied in the management of cardiomyopathies associated with post‑myocardial infarction remodeling, where it may attenuate fibrosis and improve ventricular function. Finally, emerging evidence suggests potential benefit in mitigating the severity of COVID‑19–associated acute respiratory distress syndrome by modulating the renin–angiotensin system; however, further clinical trials are required to substantiate these observations.

Adverse Effects

Common Side Effects

Patients receiving losartan may experience dizziness or light‑headedness, particularly during the initial titration period, due to hypotension. Other frequent complaints include headache, nasopharyngitis, fatigue, and gastrointestinal disturbances such as nausea or diarrhea. These effects are generally mild and transient, often resolving with continued therapy or dose adjustment.

Serious or Rare Adverse Reactions

Serious adverse reactions, while uncommon, encompass hyperkalemia, renal function deterioration, angioedema, and hypotensive shock. The risk of hyperkalemia is heightened when losartan is combined with potassium‑sparing diuretics, potassium supplements, or other agents that inhibit aldosterone synthesis. Monitoring of serum potassium and creatinine is recommended, particularly in patients with renal impairment or advanced age. Angioedema, although rare, may manifest as swelling of the lips, tongue, or airway, necessitating immediate discontinuation of therapy and supportive care. Hypotensive shock has been reported in cases of abrupt withdrawal of antihypertensive therapy, indicating the importance of tapering in patients transitioning off losartan.

Black Box Warnings

Losartan carries a black‑box warning for use during pregnancy, specifically in the second and third trimesters, due to the risk of fetal renal dysgenesis and anuria. Consequently, it is contraindicated in pregnancy. Additionally, a boxed warning advises caution in patients with impaired renal function, as accumulation may lead to hyperkalemia and renal failure. Patients should be advised to report any signs of swelling, shortness of breath, or sudden weight change, which may indicate fluid retention or renal compromise.

Drug Interactions

Major Drug–Drug Interactions

Losartan may interact with medications that influence serum potassium levels. Potassium‑sparing diuretics (e.g., spironolactone, triamterene), potassium supplements, and sodium‑glucose cotransporter‑2 inhibitors can elevate potassium concentrations, raising the risk of hyperkalemia. Concomitant use with nonsteroidal anti‑inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of losartan by reducing renal perfusion and decreasing glomerular filtration. Additionally, high‑dose diuretics may potentiate hypotension when combined with losartan. Careful monitoring and dose adjustments are advised when these agents are co‑administered.

Contraindications

Losartan is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. It is also contraindicated during pregnancy, particularly in the second and third trimesters, as well as in patients with significant renal impairment (creatinine clearance <30 mL·min^-1) unless low‑dose therapy is justified. Use in patients with hyperkalemia or a history of recurrent hyperkalemia is discouraged unless stringent monitoring is feasible.

Special Considerations

Use in Pregnancy/Lactation

Due to teratogenic risks, losartan is contraindicated in pregnancy, especially from the second trimester onward. In lactation, the drug is excreted in human milk in negligible amounts; however, given its pharmacologic potency, clinicians often recommend discontinuation during breastfeeding, particularly in the first six months postpartum. The risk–benefit ratio should be carefully evaluated when managing hypertensive disorders in pregnant patients, with alternative agents such as labetalol or nifedipine considered.

Pediatric Considerations

Clinical data on losartan in pediatric populations are limited. Dosage recommendations for children are extrapolated from adult data, adjusted for body surface area and weight. Pediatric use is generally reserved for hypertension secondary to renal disease or cardiac anomalies, with careful monitoring of blood pressure, renal function, and serum electrolytes. The safety profile appears acceptable, though further controlled studies are warranted to establish definitive dosing guidelines.

Geriatric Considerations

Elderly patients exhibit increased sensitivity to hypotensive effects, necessitating lower initial dosing and gradual titration. Age‑related reductions in renal function may also impair clearance, thereby elevating plasma concentrations. Consequently, serum potassium and creatinine should be frequently monitored, especially in the presence of concomitant diuretic therapy. Cognitive decline or orthostatic hypotension may further complicate management, requiring individualized therapeutic plans.

Renal/Hepatic Impairment

In patients with moderate renal impairment, dosage reduction to 50 mg daily is recommended, while severe impairment warrants a maximum of 25 mg daily. The drug’s renal elimination is the principal pathway; thus, accumulation can occur in renal dysfunction. Hepatic impairment has minimal impact on losartan clearance due to the predominance of renal excretion. Nevertheless, caution is advised when treating patients with coexisting hepatic disease, as altered protein binding may affect free drug concentrations.

Summary/Key Points

• Losartan is a selective AT₁ receptor antagonist, forming an active metabolite (EXP3174) that amplifies therapeutic effect.
• The drug reduces systemic vascular resistance and promotes natriuresis through blockade of angiotensin II signaling.
• Bioavailability is limited by first‑pass metabolism; however, active metabolite formation compensates, supporting once‑daily dosing.
• Approved uses encompass essential hypertension, diabetic nephropathy, and heart failure with reduced ejection fraction; off‑label indications include preeclampsia and post‑myocardial infarction remodeling.
• Common adverse effects include dizziness, headache, and gastrointestinal upset; serious risks involve hyperkalemia, renal dysfunction, and angioedema.
• Drug interactions with potassium‑sparing agents and NSAIDs necessitate monitoring; contraindications include pregnancy and severe renal impairment.
• Special populations require dose adjustments: reduced doses for renal impairment, cautious use in the elderly, and limited pediatric data.

Clinical pearls: Initiate therapy at low doses and titrate based on tolerance and blood pressure response. Monitor serum potassium and renal function at baseline and periodically thereafter. Educate patients on the signs of hyperkalemia and hypotension. When managing patients with multiple antihypertensives, consider the additive effects on renal perfusion and potassium balance.

References

1. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
2. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
3. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
4. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
5. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
8. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.